Investor List:

Top Pharmaceuticals Seed Investors in London (34)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Pharmaceuticals investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Pablo Lubroth
Pablo Lubroth
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Seed), Investors in AI (Series A), Investors in Consumer Health (Series B), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Hardware (Seed), Investors in Diverse Investors (Other Lists), Investors in Hardware (Series B), Investors in Hardware (Series A), Investors in Consumer Health (Series A), Investors in Hardware (Series B), Investors in AI (Series B), Investors in Consumer Health (Seed), Investors in Consumer Health (Seed), Investors in AI (Series A), Investors in AI (Seed), Investors in Hardware (Seed), Investors in Hardware (Seed), Investors in Consumer Health (Series A), Investors in Hardware (Series B), Investors in Consumer Health (Series A), Investors in AI (Series A), Investors in Hardware (Series A), Investors in Hardware (Series A), Investors in Consumer Health (Series B), Investors in Hardware (Pre-seed), Investors in Consumer Health (Series B), Investors in AI (Series B), Investors in AI (Series B), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Series B), Investors in Direct-to-Consumer (DTC) (Seed), Investors in Direct-to-Consumer (DTC) (Series A), Investors in Hardware (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Hardware (Pre-seed), Investors in AI (Pre-seed), Investors in AI (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in AI (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in Direct-to-Consumer (DTC) (Pre-seed), Investors in AI (Seed), Investors in AI (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Series B), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Series A), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series B), Investors in BioTech (Pre-seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed)
Photo of Hussein Kanji, Analyst at Hoxton Ventures
Hussein Kanji
Sweet spot: $2.0M
Range: $1M - $3.0M
Investors in United Kingdom, Investors in London
Investors in Retail (Seed), Investors in Analytics (Series A), Investors in Pharmaceuticals (Seed), Investors in Security (Seed), Investors in Analytics (Seed), Investors in Retail (Series A), Investors in Security (Series A), Investors in AI (Seed), Investors in Diverse Investors (Other Lists), Investors in AI (Series A), Investors in Pharmaceuticals (Series A), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Analytics (Seed), Investors in Marketplaces (Series A), Investors in AI (Seed), Investors in Investors who invested in diverse founders (Other Lists), Investors in Consumer Internet (Seed), Investors in Marketplaces (Seed), Investors in Consumer Internet (Seed), Investors in Retail (Seed), Investors in SaaS (Seed), Investors in Security (Seed), Investors in Pharmaceuticals (Seed), Investors in AI (Series A), Investors in Analytics (Series A), Investors in Consumer Internet (Series A), Investors in Marketplaces (Series A), Investors in Retail (Series A), Investors in Security (Series A), Investors in SaaS (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Retail (Pre-seed), Investors in Analytics (Pre-seed), Investors in Security (Pre-seed), Investors in AI (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in AI (Pre-seed), Investors in Analytics (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in SaaS (Pre-seed), Investors in Security (Pre-seed), Investors in Marketplaces (Pre-seed), Investors in Retail (Pre-seed), Investors in SaaS (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Consumer Internet (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in SaaS (Series A), Investors in Consumer Internet (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Marketplaces (Seed), Investors in SaaS (Seed)
Photo of Robert Thong, Venture Partner at Selvedge Venture
Robert Thong
Selvedge Venture·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Enterprise (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Health IT (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Enterprise (Seed)
KV
Kris Vulgan
Ferocity Capital·General Partner
Sweet spot: $250K
Range: $5K - $2.0M
Investors in London, Investors in California
Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Manufacturing (Seed), Investors in Pharmaceuticals (Series A), Investors in Chemicals (Seed), Investors in Cybersecurity (Pre-seed), Investors in Manufacturing (Seed), Investors in DeepTech (Pre-seed), Investors in Chemicals (Series A), Investors in AI (Series A), Investors in Semiconductors (Seed), Investors in Semiconductors (Pre-seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Semiconductors (Series A), Investors in AI (Seed), Investors in Manufacturing (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in AI (Seed), Investors in AI (Pre-seed), Investors in Manufacturing (Series A), Investors in DefenseTech (Other Lists), Investors in DeepTech (Series A), Investors in Semiconductors (Seed), Investors in Pharmaceuticals (Seed), Investors in Investors who were founders (Other Lists), Investors in Chemicals (Seed), Investors in AI (Series A), Investors in Diagnostics (Series A), Investors in Chemicals (Series A), Investors in Semiconductors (Series A), Investors in BioTech (Pre-seed), Investors in Cybersecurity (Series A), Investors in London (Other Lists), Investors in Pharmaceuticals (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Cybersecurity (Seed), Investors in Cybersecurity (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in DefenseTech (Other Lists), Investors in Diagnostics (Seed), Investors in Cybersecurity (Series A), Investors in DeepTech (Series A), Investors in Cybersecurity (Pre-seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in DefenseTech (Other Lists), Investors in BioTech (Pre-seed), Investors in DeepTech (Seed), Investors in Manufacturing (Pre-seed), Investors in Chemicals (Pre-seed), Investors in DeepTech (Seed), Investors in Diagnostics (Pre-seed), Investors in DefenseTech (Other Lists), Investors in Chemicals (Pre-seed), Investors in Semiconductors (Pre-seed), Investors in DefenseTech (Other Lists), Investors in DeepTech (Pre-seed), Investors in AI (Pre-seed), Investors in DefenseTech (Other Lists), Investors in DefenseTech (Other Lists), Investors in Manufacturing (Pre-seed), Investors in DefenseTech (Other Lists), Investors in DefenseTech (Other Lists), Investors in DefenseTech (Other Lists), Investors in DefenseTech (Other Lists), Investors in DefenseTech (Other Lists)
Photo of Timothy Haines, Managing Partner at Abingworth
Timothy Haines
Abingworth·Managing Partner
Sweet spot: $22.5M
Range: $15.0M - $30.0M
Investors in London
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists)
Photo of Loukas Saridis, Managing Director at Yarrow Capital
Loukas Saridis
Yarrow Capital·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in SMB Software (Seed), Investors in Pharmaceuticals (Seed), Investors in SMB Software (Series A), Investors in Logistics (Seed), Investors in Logistics (Series A), Investors in Pharmaceuticals (Series A), Investors in SMB Software (Seed), Investors in Pharmaceuticals (Seed), Investors in Logistics (Seed), Investors in SMB Software (Series A), Investors in Logistics (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists)
Photo of Bali Muralidhar, Managing Partner at Abingworth
Bali Muralidhar
Abingworth·Managing Partner
Sweet spot: $22.5M
Range: $15.0M - $30.0M
Investors in London
Photo of Andrew Kozlov, Managing Partner at 4BIO Capital
Andrew Kozlov
4BIO Capital·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A)